Please assess the completion status of the following clinical trial:

Trial Title: Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I or II women~* Aged 20 65 years, and scheduled for gynecologic laparoscopic surgery and IV patient-controlled analgesia (PCA) for postoperative pain control.~Exclusion Criteria:~* Known allergy or intolerance to the study drug~* History of cardiac arrhythmia~* Psychiatric illness~* Chronic treatment with a dopamine antagonist~* Use of opioids or steroids within one week of surgery~* Use of antiemetic within 24 hours before the study~* No ability to use the PCA device~* Gastrointestinal, renal, or hepatic disease~* Insulin-dependent diabetes or obesity with a body mass index \> 35 kg/m2.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- dexamethasone (Type: PLACEBO_COMPARATOR): dexamethasone 5mg iv during anesthesia induction
- dexamethasone, haloperiol 1mg (Type: ACTIVE_COMPARATOR): dexamethasone 5mg iv during anesthesia induction \& haloperidol 1mg iv 30 min before end of anesthesia
- dexamethasone + haloperidol 2mg (Type: ACTIVE_COMPARATOR): dexamethasone 5mg iv during anesthesia induction \& haloperidol 2mg iv 30 min before end of anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).